Your China–Malaysia Medical Device Regulatory Bridge
For a Chinese medical device manufacturer planning to enter Malaysia, the NMPA and MDA systems are similar in their risk-based approach, but the registration pathway, classification, conformity assessment and role of the local stakeholders are materially different. Below is a practical comparison based on the current requirements: Market-entry requirement China Malaysia Regulatory authority NMPA MDA Product classification Class I, II, III Class A, B, C, D Foreign manufacturer’s local representative Required – overseas applicant must appoint a domestic Chinese enterprise legal person as agent Required – foreign manufacturer must appoint a local Independent Authorized Representative (AR) Local representative’s role Acts as regulatory agent for registration/filing and assists the overseas registrant in fulfilling legal obligations Acts as the manufacturer’s regulatory representative and is responsible for registration and regulatory obligations under Act 737. Product approval Class I: filing; Class II & III: registration Class A, B, C, D require MDA registration before being placed on market Who submits product registration Overseas manufacturer/applicant through its Chinese legal-entity agent Malaysian AR on behalf of the foreign manufacturer Regulatory pathway for foreign devices Class I filing; Class II & III registration by NMPA Conformity assessment by CAB; Registration by MDA; Class A: Exempt CAB conformity assessment Evidence of approval in country of origin Generally, imported devices require a marketing certificate from the competent authority of the country/region where applicant or manufacturing site is located, subject to exceptions No general requirement equivalent to China’s imported-device marketing-certificate requirement; MDA has its own conformity-assessment/registration framework Local establishment licence No Require licensed AR, importer and distributor Importer requirement Importer operates within China’s import/trade framework; the NMPA registration agent is the key regulatory local entity Importer must hold an MDA establishment licence and be appointed by the AR Distributor requirement for market entry Not a separate NMPA product-registration prerequisite in the same way as Malaysia’s establishment licensing system Distributor must hold an MDA establishment licence and be appointed by the AR Language Documents must be submitted in Chinese; foreign originals are also provided where applicable Documents must be submitted in Malay or English; foreign originals are also provided where applicable Clinical evaluation Require for Class II & III Require for Class B, C and D QMS China Medical Device GMP; ISO13485 is not mandatory ISO 13485 mandatory for all Class A, B, C & D, except some class A devices Can the foreign manufacturer enter directly? No, requires a Chinese domestic enterprise legal-entity agent for imported-device registration/filing No, foreign manufacturer needs a Malaysian AR Main market-entry bottleneck NMPA product registration, particularly Class II/III Product registration plus local establishment licensing structure Regulatory reliance Primarily NMPA’s own evaluation framework MDA has increasingly adopted reliance/verification mechanisms Online system NMPA registration systems MeDC@St Recognize foreign pre-market clearance? Yes, as supporting evidence Yes, for recognised foreign authorities under the verification pathway Further reference about NMPA vs MDA — Recognition of Foreign Pre-Market Approval. Further reference about Malaysia Medical Device Regulatory Affairs: Overview of Regulatory Framework and Requirements. Enter Malaysia with the Right Regulatory Partner Global Rep is trusted by many Chinese manufacturers as their local authorized representative for medical devices in Malaysia, securing medical device registrations for market entry. We evaluate and appoint importers and distributors, manage postmarket surveillance, and maintain registrations to ensure ongoing compliance. As your reliable business partner, Global Rep empowers you to enter and expand in Malaysia while giving you flexibility in shaping your marketing strategy. Still unsure what is required? Book a complementary 30 minutes market entry review session with us.
China NMPA vs Malaysia MDA — Recognition of Foreign Pre-Market Approval
Recognition of foreign pre-market approvals is a clear and growing global trend in medical-device regulation. The terminology varies—regulatory reliance, abridged review, verification, recognition of overseas assessments, etc.—but the underlying principle is the same: Regulators increasingly leverage the work already performed by trusted foreign regulators instead of repeating the entire assessment from scratch. Historically, a manufacturer entering each country generally had to undergo a separate national regulatory assessment: Foreign approval → New national assessment → New national approval The emerging model is: Trusted foreign approval → Reliance / verification / abridged review → Faster national market access This is being driven by the need to reduce regulatory duplication, shorten time-to-market, conserve regulatory resources and improve patient access. However, this concept has yet to be fully accepted by many authorities. The following comparison highlights a key difference between China NMPA and Malaysia MDA in their treatment of foreign pre-market approvals. Aspect China NMPA Malaysia MDA Accepts foreign pre-market approval? Yes, as supporting evidence Yes, for recognised foreign authorities under the verification pathway Does foreign approval replace local approval? No No Can foreign approval reduce local assessment? No Yes Formal verification/reliance pathway? No Yes Foreign authorities recognised? Foreign competent-authority marketing certificate is required for imported devices, as supporting evidence Yes. MDA maintains a defined list of recognised competent authorities Use of foreign technical/clinical evidence Yes, subject to NMPA requirements Yes, through verification of evidence Local conformity assessment repeated? Generally, NMPA performs its own regulatory review Full assessment can be avoided/reduced if eligible for verification Local product registration still required? Yes Yes While NMPA accepts foreign regulatory approvals as supporting evidence for imported medical devices, manufacturers must generally undergo NMPA’s own regulatory review and foreign approval does not reduce the local assessment in a broad reliance pathway. In contrast, MDA has established a formal verification pathway that allows eligible medical devices with approvals from recognised foreign regulatory authorities to leverage existing conformity-assessment evidence, potentially reducing duplication of assessment, regulatory time and cost. The eligibility criteria for accessing Malaysia’s Conformity Assessment by Way of Verification Route are set out in the Medical Device Authority (MDA) Guidance Document. In both markets, foreign approval does not replace local market authorisation; NMPA or MDA approval remains necessary before the device can be placed on the respective market. Medical device pre-market approval can be a lengthy and costly process. By recognising eligible foreign pre-market approvals, Malaysia MDA has significantly accelerated market entry and reduced regulatory costs, making Malaysia a more attractive gateway for medical device manufacturers seeking access to the Malaysian and regional market. The following table provides a comparison of the typical market-entry turnaround time and estimated regulatory costs for medical device registration under China NMPA and Malaysia MDA. China NMPA Malaysia MDA TAT CAB conformity assessment Not applicable Class B–D: 30 – 60 working days after complete submission Regulatory evaluation Class I: 5 working days Class II: 60 working days Class III: 90 working days Class A–D: 30 – 60 working days after complete submission Typical overall time Class II: ~12–24+ months Class III: ~18–36+ months Class B, C & D: ~3–5+ months Cost Regulatory evaluation Class I: Not required Class II: RMB 210,900 ≈ US$29,500 Class III: RMB 308,800 ≈ US$43,200 Class A: RM1,250 ≈ US$315 Class B: RM1,250 ≈ US$315 Class C: RM2,500 ≈ US$625 Class D: RM3,750 ≈ US$940 CAB full conformity assessment (FCA) Not applicable Class B: ~ US$3,750 Class C: ~ US$6,250 Class D: ~ US$8,750 CAB conformity assessment via verification route (VR) Not applicable Class B, C & D: ~ US$300 Estimated total market-entry cost (excluding profession regulatory affairs supports fee) Class II: ~US$30,000 Class III: ~US$50,000 Class A: ~ US$315 Class B: ~ US$4,500 (FCA)/650 (VR) Class C: ~ US$6,500 (FCA)/ 950 (VR) Class D: ~ US$10,000 (FCA)/1,250 (VR) Relative cost Higher Lower Relative speed Slower Faster In our blog, “Which Southeast Asian Country Should You Enter First?”, Malaysia is identified as a “practical regional entry point” for foreign medical device manufacturers looking to test the market, gain ASEAN experience, and establish a foundation for regional expansion. Find the Right Regulatory Pathway into Malaysia If your medical devices have already obtained pre-market clearance from an MDA-recognised reference authority, we invite you to contact Global Rep to assess your regulatory readiness and identify the most efficient pathway to enter the Malaysian and wider regional markets. With an established market portfolio and extensive experience supporting Chinese medical device manufacturers, Global Rep understands the regulatory and commercial challenges of expanding into Malaysia and ASEAN. Our practical market experience, together with positive testimonials from Chinese manufacturers we have supported, demonstrates our commitment to delivering reliable, responsive and cost-effective regulatory solutions.
Which Southeast Asian Country Should You Enter First? A Medical Device Manufacturer’s Guide
For a medical device manufacturer planning to expand into Southeast Asia, one of the first questions is often: “Which country should we enter first?” Malaysia? Singapore? Indonesia? Thailand? The Philippines? Brunei? There is no universal answer. The largest market is not necessarily the best first market. The right starting point depends on your product, regulatory status, commercial objectives, available resources, local partners and long-term regional strategy. A well-chosen first market can do more than generate your first sales. It can help you build regulatory experience, establish distribution, understand customer needs and create a foundation for expansion across Southeast Asia. Six Markets, Six Different Opportunities Southeast Asia is not one homogeneous market. Each country offers a different combination of market size, healthcare infrastructure, regulatory environment, business accessibility and strategic value. Factor Malaysia Singapore Thailand Indonesia Philippines Brunei Market opportunity Attractive Smaller Large Very large Large Small but focused Healthcare ecosystem Developed Highly developed Developed Developing Developing Developed Regulatory maturity Established Highly developed Established Developing Developing Developing / evolving Regional gateway potential High Very high High High High Limited Relative market-entry cost Accessible Higher Moderate Moderate–higher Moderate Moderate Local partner importance High High High High High Very high Market accessibility Accessible Accessible Moderate More complex Accessible Focused Strategic role Practical entry point Regional hub Mainland SEA expansion Large-market expansion English-speaking SEA market Focused, high-value market Best suited for Market testing & regional expansion Regional positioning Mainland SEA opportunities Scale & long-term growth English-speaking market development Specialised opportunities & targeted sales This following is a strategic comparison, not a ranking. The most suitable first market will vary from one manufacturer to another. Country Strategic opportunity May suit manufacturers looking to… Malaysia Practical regional entry point Test the market and build an ASEAN foundation Singapore Regional hub & highly developed healthcare market Build regional credibility and serve sophisticated customers Indonesia Large long-term opportunity Access a substantial and growing market Thailand Major mainland Southeast Asian market Develop healthcare and private-sector opportunities Philippines Large English-speaking market Build an accessible English-speaking commercial market Brunei Small, high-income market Pursue targeted opportunities with a focused strategy 1. Malaysia — A Practical Starting Point Malaysia can be an attractive starting point for foreign medical device manufacturers that want to establish a presence in Southeast Asia without immediately committing substantial resources to a large regional operation. Malaysia has an established medical device regulatory framework administered by the Medical Device Authority (MDA). A foreign manufacturer can appoint a Malaysian Authorized Representative (AR) to represent it for regulatory purposes, while licensed importers and distributors can support its commercial activities. This means a manufacturer can potentially establish a Malaysian market presence without setting up its own Malaysian company. Malaysia may therefore be particularly suitable for manufacturers that want to: test the Southeast Asian market; establish their first local regulatory presence; work with local importers and distributors; build regional experience; and use Malaysia as a foundation for subsequent ASEAN expansion. Malaysia is also becoming increasingly relevant from a regulatory-reliance perspective, making it important for manufacturers to assess how existing international approvals and regulatory evidence may support their Malaysian pathway. 2. Singapore — A Regional Hub Singapore is a relatively small market in population terms, but its healthcare ecosystem, infrastructure and international connectivity make it strategically important. For manufacturers targeting: sophisticated healthcare institutions; private healthcare groups; regional headquarters; strategic partnerships; or high-value medical technology markets, Singapore can be an attractive starting point. Singapore’s Health Sciences Authority (HSA) has an established medical device regulatory framework, including different evaluation routes depending on the device and the manufacturer’s regulatory history. Singapore can also provide strong regional positioning for companies that want to use Southeast Asia as part of a broader international strategy. However, the relatively small market and higher operating costs mean that Singapore may not be the most appropriate first market for manufacturers primarily seeking volume. 3. Indonesia — The Large-Market Opportunity Indonesia offers one of the most significant long-term market opportunities in Southeast Asia. Its large population and growing healthcare needs make it attractive for manufacturers seeking substantial commercial potential. But market size alone should not determine your first-market decision. Entering a large and geographically dispersed market can require significant investment in: regulatory compliance; local partnerships; distribution; logistics; customer development; technical support; and after-sales service. For manufacturers with limited experience in Southeast Asia, it may be strategically sensible to establish experience in another market first. 4. Thailand — A Gateway to Mainland Southeast Asia Thailand is one of the region’s important healthcare and medical device markets. Its healthcare sector includes both public and private healthcare, while its established medical tourism industry creates additional opportunities for certain medical technologies. Thailand may be particularly relevant for manufacturers targeting: hospitals; private healthcare groups; specialised medical services; medical tourism; and mainland Southeast Asian markets. A strong local distributor or established customer relationship can significantly influence whether Thailand is the right first market. 5. Philippines — A Large English-Speaking Market The Philippines offers another attractive entry point for international medical device manufacturers. Its large population and widespread use of English can make commercial communication and relationship building relatively accessible for international companies. The healthcare market includes significant private-sector participation, creating opportunities for manufacturers with the right products, pricing and local partners. Medical devices are regulated by the Philippine Food and Drug Administration (FDA), and manufacturers should assess the applicable regulatory requirements before selecting the Philippines as their entry market. For manufacturers whose regional strategy places particular importance on English-speaking markets, the Philippines can be a compelling starting point. 6. Brunei — A Focused, High-Income Market Brunei is very different from Indonesia, Thailand or the Philippines. It has a small population, but relatively high income levels and a concentrated healthcare system. That means Brunei is unlikely to be the first choice for manufacturers whose primary objective is market volume. However, its smaller and concentrated market can be attractive for manufacturers with: specialised medical devices; premium products; government or institutional opportunities; existing relationships in the country; or a distributor capable of covering the
Who Does What? Understanding MDA’s Four Establishment Roles
The regulatory framework for medical devices is inherently complex. The following table offers an overview of four key establishment roles regulated by the Medical Device Authority (MDA) in Malaysia. It provides a structured, high‑level understanding of their responsibilities, activities, and compliance obligations, serving as a foundation before examining detailed requirements. Manufacturer Authorized Representative Importer Distributor Who is it? Person/company manufacturing the medical device Malaysian representative appointed by a foreign manufacturer Person/company appointed by AR to import devices Person/company distributing devices in Malaysia Establishment license Required Required Required Required Primary regulatory role Product manufacturer + registration Local authorized representative + registration Importation Distribution Certification requirement ISO 13485 GDPMD GDPMD GDPMD Medical device registration Yes Yes No No Manufactures device Yes No No No Registers device with MDA Yes Yes No No Imports device Not under Manufacturer-only licence Not under AR-only licence Yes No Distributes device Only devices it manufactures No No Yes Appoints / controls Distributor Importers & distributors for represented devices No No Global Rep is a professional regulatory affairs service provider dedicated to simplifying complex medical device regulatory procedures. We support companies seeking to enter the medical device sector, empowering them to achieve compliance and contribute meaningful value to the healthcare industry. We offer the following: Service Solutions GDPMD certification We guide your organisation in establishing and implementing an effective GDPMD system that strengthens medical device distribution practices, ensures regulatory compliance, and prepares your team for successful certification. Further insights: GDPMD System Setup, Certification, and Establishment License Application, and Foundations of Medical Device Compliance. ISO 13485 certification Our competent ISO 13485 consultants work closely with your team to develop a compliant and practical QMS aligned with ISO 13485 standard requirements. We guide your team in designing and implementing a robust system that supports device safety and effectiveness while enabling sustainable, long-term regulatory compliance. Further insights: ISO 13485 Certification: Your Gateway to Medical Device Market Access, and Foundations of Medical Device Compliance. Independent authorized representative We hold your medical device registration independently, giving you greater control and flexibility over your marketing strategy and distribution channels. This allows you to work with multiple local distributors without having to manage separate registration requests for the same product, while maintaining the confidentiality of your product information and preserving the freedom to adapt your market strategy as your business evolves. Further insights: What Does a Local Authorized Representative Do for Medical Devices?, and Medical Device Registration Holder Options: Local Authorized Representative vs Distributor. Pre-market device registration We provide end-to-end support for medical device registration, from device classification and technical documentation to regulatory submission, evaluation and obtaining pre-market clearance, helping you bring your medical devices to market efficiently and with confidence. Further insights: Navigating Malaysia’s Medical Device Registration Process, and Medical Device Classification in Malaysia. Registration maintenance We keep your medical device registrations current with ongoing support for renewals, amendments, changes and regulatory compliance throughout the product lifecycle. Post market surveillance We maintain your regulatory compliance after market entry through structured post-market surveillance, vigilance, incident reporting and corrective action support. You don’t need to navigate complex regulatory requirements on your own. Share your marketing plans with us, and we’ll take care of the regulatory pathway—identifying the requirements, preparing the necessary documentation and managing the process to help you achieve your market-entry goals and long term compliance.
Why Can’t One Establishment Rely on Another’s Conformity Assessment?
Nowadays, turning to AI platforms for answers has become a common practice. These systems generate responses by breaking user input into tokens, processing them through a neural network known as a transformer, and predicting the most probable next word step by step until a complete answer is formed. Unlike databases, they do not “know” facts directly but rely on statistical patterns learned from extensive training data. The accuracy of AI responses depends largely on the quality of the training data, the robustness of ongoing model maintenance, and how closely real-world context aligns with the conditions under which the model was trained. Inaccuracies often arise from poor data quality, model drift, or hallucinations—where the system produces information that sounds plausible but is not factually correct. On August 29, 2026, the following question was posted simultaneously to Microsoft Copilot, Google Gemini, and ChatGPT: “Why is an establishment not permitted to register a medical device through the verification pathway by leveraging the full conformity assessment already completed by another establishment?” The responses provided by these platforms are displayed below. Microsoft Copilot response: An establishment is not permitted to use the verification pathway for a medical device that has already been registered via full conformity assessment in Malaysia because the verification route is designed exclusively for devices with recognized international premarket clearance. Google Gemini response: 1. Distinct Regulatory Purpose & Sequence Verification Route: Designed solely as an expedited, reliant assessment pathway for devices that hold valid prior approvals from MDA-recognised foreign reference authorities (e.g., US FDA, EU CE, Singapore HSA, TGA Australia). The Conformity Assessment Body (CAB) relies on the foreign review to verify local compliance rather than doing a full evaluation. Full Conformity Assessment (FCA): Designed for devices without qualified foreign reference approvals or those undergoing complete local evaluation in Malaysia. Once a device goes through FCA, its regulatory baseline for Malaysia is already established via full domestic evaluation. Re-entering through a verification pathway intended for foreign market reliance contradicts the hierarchy of the regulatory routes. 2. Duplication & Invalid Reliance Logic The verification route exists to avoid double-evaluating clinical and technical data that another trusted foreign agency has already vetted. If a medical device has already undergone Full Conformity Assessment locally, Malaysia’s CAB and MDA have already performed the highest-tier, full-dossier evaluation. Attempting to use the verification route on an already FCA-assessed device would mean asking a CAB to “verify” the device using foreign evidence for a product that has already proven its compliance via Malaysia’s own complete assessment route. 3. Maintenance and Lifecycle Pathways (Re-registration) When a device registered via Full Conformity Assessment needs to be renewed, maintained, or updated: Renewals/Re-registration: The establishment must maintain the existing conformity assessment certificate (FCA) or use MDA’s official Re-registration Route (such as the automated re-registration in MeDC@St) rather than applying for a brand-new registration under a different evaluation route. Design/Device Changes: Modifications are handled through Change Notifications (CN) under the original FCA registration baseline, not by re-filing through the Verification Route. ChatGPT response: The key point is that the verification pathway is not simply an alternative registration route that an establishment may choose whenever a device is already registered in Malaysia. It is an abridged conformity-assessment pathway based on reliance on an approval from a recognised foreign regulatory authority or notified body. Under the current MDA/GD/0070 guidance, for initial registration by verification, the device must, among other things: have approval from at least one recognised regulatory authority or notified body; have the same design and intended purpose as the device approved by that authority/body; and satisfy the specified global safety requirements. Why a device already registered by full conformity assessment is different: If the device has already gone through full conformity assessment in Malaysia, its Malaysian registration is based on the Malaysian CAB’s own assessment of the manufacturer’s conformity evidence. The verification route is intended to leverage an existing recognised foreign assessment, rather than to provide a second, abbreviated route for an already-established Malaysian registration. In other words, the regulatory logic is: Foreign recognised approval → verification/abridged assessment → Malaysian registration; Rather than: Existing Malaysian full-assessment registration → switch retrospectively to verification. The MDA guidance does, however, expressly recognise verification for re-certification/re-registration of a device that was previously registered in Malaysia. It states that, for recertification, the device may have been assessed through either full conformity assessment or verification, provided that it has a valid registration certificate and meets the other eligibility conditions. So there is an important distinction: Situation Verification pathway Device is being registered for the first time and has an eligible foreign approval Potentially yes Device already registered in Malaysia following full conformity assessment, and you want to create another initial registration using verification Generally no Device is already registered in Malaysia and is undergoing eligible re-registration/recertification Potentially yes, subject to the verification criteria The underlying regulatory reason: Allowing an establishment to take an existing Malaysian registration that was obtained through full conformity assessment and simply re-register it through verification could effectively bypass the assessment pathway that was used to establish the device’s Malaysian conformity. Verification is based on regulatory reliance on an eligible external assessment; it is not designed as a mechanism for changing the conformity-assessment basis of an existing registration. This is also consistent with MDA’s current framework, where conformity assessment is a prerequisite to registration under Section 7 of the Medical Device Act 2012, and the level/type of assessment depends on the applicable pathway and risk. Confused? Let us clarify Our technical team has conducted a comprehensive review and analysis of the AIgenerated responses. We have determined that this particular question has not yet been sufficiently addressed or discussed within available online sources. Consequently, the AI platforms appear inadequately trained to provide a complete and reliable answer at this stage.Rather than leaving the matter unresolved, we invite you to join us as we dissect and examine the question together—step by step—towards a clearer understanding. “Why is an establishment not permitted to register a medical device through the
Innovation Meets Humanism
In 2026, we are proud to have the opportunity to contribute to Malaysia’s healthcare industry by donating a batch of personal protective gowns to the Academy for Silent Mentor Training Center (AFSM). AFSM is a non-profit NGO sustained through donations, sponsorships, and community support. Based in Malaysia, AFSM is a pioneering medical education institution founded in 2012 under Universiti Malaya and formalized in 2016. Built upon the altruistic foundation of voluntary body donation, AFSM blends surgical training with empathy, compassion, and humanistic values. Its vision is clear: to nurture healthcare professionals who are not only skillful but also deeply compassionate. At the heart of this mission is Professor Dr. Chin Kin Fah, Founding Chairman and Executive Director of AFSM. He pioneered the Silent Mentor program in Malaysia, advancing voluntary body donation for medical education, surgical training, and research. His leadership continues to emphasize the integration of empathy and compassion into healthcare practice. Through international partnerships, AFSM is shaping medical education worldwide, strengthening technical expertise while cultivating humanistic values among future doctors. Ready to Bring Innovation and Medical Device Registration Compliance Together? Global Rep is honored to support this vision. Beyond donations, our strength lies in medical device regulatory affairs. As a local authorized representative and regulatory affairs partner, we guide companies through pre-market requirements such as ISO 13485 certification and GDPMD certification, medical device registration to accelerate innovation entry, and post-market regulatory obligations to ensure sustainable business operations. Together, we can shape the future of Malaysia’s healthcare industry with both innovation and compassion.